Clinical trials: Neuroendocrine Tumor Carcinoid
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and…
- Conditions
- Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
- Trial name
- NCT05263050
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fox Chase Cancer Center
Neuroendocrine Carcinoma
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine…
- Trial name
- 68Ga (NCT01396382)
- Testing
- 68Ga-DOTATATE PET scan
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with…
- Trial name
- REMAIN (NCT07842172)
- Testing
- Somatostatin Analogue(s)
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Washington University School of Medicine
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Urinary measure of 5-hydroxyindolacetic acid (5HIAA) is an important marker for the diagnosis and follow-up of patients with small-intestine neuroendocrine tumors.
- Trial name
- NCT02826928
- Testing
- blood sample withdrawn
- Where
- France
- Volunteers
- 116 people
- Sponsor
- CHU de Reims
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Pheochromocytoma, Paraganglioma
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much…
- Conditions
- Pheochromocytoma, Paraganglioma, Carcinoid
- Trial name
- NCT00339131
- Testing
- Ultratrace iobenguane I 131
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00416767
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Volunteers
- 20 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Carcinoid Tumor, Neuroendocrine Tumors
Clinical and Pathologic Studies in Neuroendocrine Tumors
This research involves the study of neuroendocrine tumors in order to better understand how the disease grows and spreads. This study requires will use tissue collected from from biopsies performed during your regular medical…
- Trial name
- NCT00657332
- Testing
- blood sample draw, urine sample
- Sponsor
- Stanford University
Carcinoid, Neuroendocrine Tumors
EPO906 in Carcinoid and Other Neuroendocrine Tumors
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid…
- Trial name
- NCT00050349
- Testing
- EPO906 epothilone B
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumors, Islet Cell (Pancreatic NET)
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing…
- Conditions
- Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
- Trial name
- NCT01980732
- Testing
- 68Ga-DOTA TATE
- Where
- United States
- Sponsor
- Andrei Iagaru
Neuroendocrine Tumor, Islet Cell Tumor
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
- Trial name
- NCT00434109
- Testing
- Sunitinib malate, Hepatic Artery Embolizations
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Neuroendocrine Carcinoma, Islet Cell Carcinoma
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Objectives: Primary endpoint: -Assess the clinical activity of RAD 001 plus depot octreotide as defined by progression free survival (PFS) duration defined by RECIST criteria in treated and untreated patients with metastatic…
- Trial name
- NCT00113360
- Testing
- RAD001, Octreotide Depot
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
ALG-LungCancerRegistry (SAFRO2202)
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Carcinoid Tumor
- Trial name
- SAFRO2202 (NCT07161882)
- Testing
- Observational Data Collection
- Where
- 21 sites in Algeria
- Volunteers
- 3,750 people
- Sponsor
- Société Algérienne de Formation et de Recherche en Oncologie
Neuroendocrine Tumor
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects.
- Trial name
- NCT00789841
- Testing
- Magnetic Tracking System (MTS) and radio-opaque markers
- Where
- Denmark
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics